Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy
CM Montagnon, JS Lehman, DF Murrell… - Journal of the American …, 2021 - Elsevier
Intraepithelial autoimmune blistering dermatoses are a rare group of skin disorders
characterized by disruptions of inter-keratinocyte connections within the epidermis through …
characterized by disruptions of inter-keratinocyte connections within the epidermis through …
Adverse outcome and severity of COVID‐19 in patients with autoimmune bullous diseases: a historical cohort study
The ongoing COVID‐19 pandemic has raised concerns regarding the outcome of this
infection in patients with autoimmune bullous dermatoses (AIBDs) due to effect of drugs …
infection in patients with autoimmune bullous dermatoses (AIBDs) due to effect of drugs …
Impact of COVID-19 on autoimmune blistering diseases
K Drenovska, S Vassileva, I Tanev, P Joly - Clinics in Dermatology, 2021 - Elsevier
Since the beginning of the COVID-19 outbreak, attention has gradually moved from the
respiratory manifestations of the disease toward its dermatologic aspects. The need for …
respiratory manifestations of the disease toward its dermatologic aspects. The need for …
COVID‐19 severity and SARS‐Cov‐2 vaccine safety in pemphigus patients
Z Özgen, H Aksoy, Ö Akın Çakıcı… - Dermatologic …, 2022 - Wiley Online Library
There are safety concerns in the treatment of pemphigus patients with immunosuppressants,
particularly rituximab (RTX), in times of the COVID‐19 pandemic. In the beginning, the …
particularly rituximab (RTX), in times of the COVID‐19 pandemic. In the beginning, the …
[PDF][PDF] SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Repor
L Róbert, A Kovács, M Sárdy, M Fábián - Acta Dermatovenerologica …, 2023 - hrcak.srce.hr
The mortality risk factors for Corona Virus Disease-19 (COVID-19) infection (caused by the
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)) include advanced age …
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)) include advanced age …
Rituximab Administration in Coronavirus Pandemic Era: A Mini-Review of Clinical Evidence
A Shamabadi, H Mahmoudi… - Journal of Iranian …, 2021 - publish.kne-publishing.com
Rituximab (RTX), as a B cell-depleting agent, is indicated in treating several malignancies
and autoimmune diseases. The management of patients currently receiving RTX and …
and autoimmune diseases. The management of patients currently receiving RTX and …